- Home
- AUUD vs REVB Comparison
AUUD vs REVB Comparison
Compare AUUD & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- REVB
- Stock Information
- Founded
- AUUD 2012
- REVB 2020
- Country
- AUUD United States
- REVB United States
- Employees
- AUUD N/A
- REVB N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- REVB Health Care
- Exchange
- AUUD Nasdaq
- REVB Nasdaq
- Market Cap
- AUUD 3.8M
- REVB 3.2M
- IPO Year
- AUUD 2021
- REVB N/A
- Fundamental
- Price
- AUUD $0.70
- REVB $0.85
- Analyst Decision
- AUUD Hold
- REVB
- Analyst Count
- AUUD 1
- REVB 0
- Target Price
- AUUD N/A
- REVB N/A
- AVG Volume (30 Days)
- AUUD 175.0K
- REVB 183.6K
- Earning Date
- AUUD 11-12-2024
- REVB 11-11-2024
- Dividend Yield
- AUUD N/A
- REVB N/A
- EPS Growth
- AUUD N/A
- REVB N/A
- EPS
- AUUD N/A
- REVB N/A
- Revenue
- AUUD N/A
- REVB N/A
- Revenue This Year
- AUUD N/A
- REVB N/A
- Revenue Next Year
- AUUD N/A
- REVB N/A
- P/E Ratio
- AUUD N/A
- REVB N/A
- Revenue Growth
- AUUD N/A
- REVB N/A
- 52 Week Low
- AUUD $0.54
- REVB $0.70
- 52 Week High
- AUUD $11.75
- REVB $25.26
- Technical
- Relative Strength Index (RSI)
- AUUD 50.20
- REVB 48.36
- Support Level
- AUUD $0.54
- REVB $0.77
- Resistance Level
- AUUD $0.63
- REVB $0.82
- Average True Range (ATR)
- AUUD 0.05
- REVB 0.04
- MACD
- AUUD 0.02
- REVB 0.02
- Stochastic Oscillator
- AUUD 80.98
- REVB 79.43
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products include Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).